Click here to go to the previous page
Challenging Cases in the Management of Newly Diagnosed and Recurrent Prostate Cancer
Program Code:
EDU211
Date:
Monday, September 22, 2008
SPEAKER(S):
Click the plus sign to see more detailed information
about each speaker.
Anthony D'Amico, Radiation Oncologist,
Brigham and Womens Hospital and Dana Farber Cancer
International Expert in detection, staging and management of prostate cancer
|
Professor James William Denham
Jim Denham did his postgraduate training in England at Leeds, and at the Mount Vernon and Middlesex Hospitals, London. He received his professional diploma in 1980 and was awarded his research doctorate in 1983.
In 1983 he moved to Australia with his wife Liz, and commenced his specialist career in Adelaide. He became head of the Newcastle department in 1987.
His keen interest in clinical research continued in Australia and he was co-founder of the multi-centre Australia and New Zealand trials group, TROG, in 1987. Later he lead TROG’s oesophageal and prostate cancer trials. The latter two 96.01 and RADAR prostate cancer trials are Australia and New Zealand’s largest cancer trials having enrolled 818 and 1071 men respectively.
In 1992 he was awarded professional status by the University of Newcastle. His work as attracted $Aus7.8M in competitive funding and a further $Aus5M in industry funding. He has published 124 full length papers in international journals to date and has been invited to speak at numerous international conferences. He is a regular review for numerous international journals and is an Editorial Board member of Radiotherapy and Oncology.
|
am a practicing urologic oncologist with experience in all forms of therapy for localized prostate cancer
|
W. Robert Lee, Professor, Duke University School of Medicine
Chris Parker,
M.D.,
The Insitute of Cancer Research, Royal Marsden Hospital
Chief investigator of the MRC RADICALS trial of adjuvant treatment after radical prostatectomy.
UK principal investigator of the NCIC START trial of selective treatment against radical therapy.
Principal investigator of the Royal Marsden prospective cohort study of active surveillance of localised prostate cancer.
Member of the NICE Prostate Cancer Guideline Development Group.
|
LEARNER OUTCOMES:
-
Apply the randomized data regarding adjuvant radiation therapy to the patient with pT3 or margin + disease
-
Apply the randomized data regarding dose escalation and hormonal therapy to the management of men with newly diagnosed localized prostate cancer
-
Apply the randomized data regarding the integration of radiation therapy and hormonal therapy to men with locally advanced prostate cancer